R Childs

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint High-dose chemotherapy and allogeneic immunotherapy
    Richard Childs
    Hematology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 366:273-5. 2005
  2. ncbi request reprint Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    N Engl J Med 343:750-8. 2000
  3. ncbi request reprint Allogeneic stem cell transplantation for renal cell carcinoma
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1501, USA
    Curr Opin Urol 11:495-502. 2001
  4. ncbi request reprint Nonmyeloablative allogeneic immunotherapy for solid tumors
    Richard W Childs
    Allogeneic Hematopoietic Cell Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 55:459-75. 2004
  5. ncbi request reprint Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma
    R W Childs
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Crit Rev Immunol 21:191-203. 2001
  6. ncbi request reprint The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy
    Richard W Childs
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Nephrol 10:227-34. 2002
  7. ncbi request reprint A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Bone Marrow Transplant 37:353-8. 2006
  8. ncbi request reprint Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
    R Nakamura
    Stem Cell Transplantation Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 115:95-104. 2001
  9. ncbi request reprint Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
    M E Horwitz
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 344:881-8. 2001
  10. ncbi request reprint Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
    R Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892 1652, USA
    Br J Haematol 131:74-9. 2005

Detail Information

Publications53

  1. ncbi request reprint High-dose chemotherapy and allogeneic immunotherapy
    Richard Childs
    Hematology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 366:273-5. 2005
  2. ncbi request reprint Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    N Engl J Med 343:750-8. 2000
    ....
  3. ncbi request reprint Allogeneic stem cell transplantation for renal cell carcinoma
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1501, USA
    Curr Opin Urol 11:495-502. 2001
    ..This article reviews the design, methodology and early clinical results of studies investigating the use of allogeneic stem cell transplantation in metastatic renal cell carcinoma...
  4. ncbi request reprint Nonmyeloablative allogeneic immunotherapy for solid tumors
    Richard W Childs
    Allogeneic Hematopoietic Cell Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 55:459-75. 2004
    ..The improved safety and preliminary success of this transplant approach have justified applying allogeneic immunotherapy to patients with treatment-refractory solid tumors...
  5. ncbi request reprint Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma
    R W Childs
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Crit Rev Immunol 21:191-203. 2001
    ..This article reviews the results of a pilot trial demonstrating graft-versus-renal cell carcinoma effects following nonmyeloablative stem cell transplantation, highlighting the potential of allogeneic immunotherapy for treating cancer...
  6. ncbi request reprint The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy
    Richard W Childs
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Nephrol 10:227-34. 2002
    ..These preliminary studies provide additional evidence supporting the susceptibility of RCC to immune attack and lay the foundation for future targeted allo-immune-based cancer strategies...
  7. ncbi request reprint A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Bone Marrow Transplant 37:353-8. 2006
    ..The GvMC effect can be observed after nonmyeloablative HCT with limited efficacy. Effective cytoreductive therapy prior to HCT may be required for long-term disease control and cure...
  8. ncbi request reprint Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
    R Nakamura
    Stem Cell Transplantation Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 115:95-104. 2001
    ..83 x 10(5) CD3(+) cells/kg. These results further define the impact of CD34 and CD3 cell dose on transplant outcome and show that careful dosing of stem cells and lymphocytes may permit the control and optimization of transplant outcome...
  9. ncbi request reprint Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
    M E Horwitz
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 344:881-8. 2001
    ..We investigated the feasibility of stem-cell transplantation without ablation of the recipient's bone marrow...
  10. ncbi request reprint Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
    R Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892 1652, USA
    Br J Haematol 131:74-9. 2005
    ..Membranous nephropathy resulting in NS is a previously unrecognised and clinically significant complication of non-myeloablative HCT...
  11. ncbi request reprint Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
    B N Savani
    Stem Cell Transplantation Section, Hematology Branch, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 21:2145-52. 2007
    ..7, P=0.028) and improved survival (HR 11.4, P=0.03). Results suggest that T cell-depleted SCT might be improved and the GVL effect enhanced by selecting donors with favorable KIR genotype, and by optimizing CD34 and CD3 doses...
  12. ncbi request reprint CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML
    S Ito
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Bone Marrow Transplant 48:1313-6. 2013
    ..2 years, CMV reactivation < day 100 as a time-dependent covariate was an independent factor associated with decreased relapse. We conclude that CMV reactivation may contribute to a beneficial GVL effect in CML transplant recipients. ..
  13. ncbi request reprint Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation
    S R Solomon
    Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Bathesda, MD 20892, USA
    Bone Marrow Transplant 31:783-8. 2003
    ..Similarly, no significant differences were found in chronic GVHD, transplant-related mortality, or survival. These results define a role for CSA in preventing GVHD at low T-cell doses following PBSCT...
  14. ncbi request reprint Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis
    R Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Br J Haematol 124:777-86. 2004
    ..0001). These data suggest that a co-ordinated approach using immunoregulatory monoclonal antibodies, pre-emptive antimicrobial therapy and judicious steroid withdrawal can dramatically improve outcome in steroid-refractory aGVHD...
  15. ncbi request reprint Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation
    B N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Building 10, Hatfield CRC, 10 Center Drive MSC 1202, Bethesda, MD 20892 1202, USA
    Bone Marrow Transplant 36:1009-15. 2005
    ..Four patients receiving nonconcurrent DLI+IM are also alive in MR. In conclusion, DLI appears to synergize with IM to induce rapid and durable MR...
  16. ncbi request reprint Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    M F Bevans
    Department of Nursing, National Institutes of Health, Bethesda, MD 20892, USA
    Bone Marrow Transplant 38:101-9. 2006
    ..Two-year survivors report a return to baseline or better in HRQL by day 100, with the exception of physical health in MT patients...
  17. ncbi request reprint Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease
    M R Robinson
    National Eye Institute NIH, 10 10S229, 110 Center Drive, MSC 1863, Bethesda, MD 20892 1863, USA
    Bone Marrow Transplant 33:1031-5. 2004
    ..Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial...
  18. ncbi request reprint Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population
    K J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 184:1093-7. 2001
    ..A chain of transmission within the outpatient clinic appeared to have occurred in 4 outpatients and to have extended to 2 hospitalized patients. Molecular epidemiology was useful in discerning routes of transmission in this outbreak...
  19. doi request reprint Active thrombopoiesis is associated with worse severity and activity of chronic GVHD
    T Bat
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Bone Marrow Transplant 48:1569-73. 2013
    ..Among patients with stable moderate or severe cGVHD, there was no evidence of hypoproduction of platelets. Future studies should further investigate the role of thrombopoiesis in cGVHD. ..
  20. ncbi request reprint High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD 20892, USA
    Bone Marrow Transplant 30:235-42. 2002
    ..This strategy was associated with effective control of CMV antigenemia in the majority of patients and near-complete eradication of fatal CMV IP...
  21. ncbi request reprint Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation
    F van Rhee
    Bone Marrow Transplant Unit, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Br J Haematol 105:1014-24. 1999
    ....
  22. ncbi request reprint What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma
    Naoto T Ueno
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:31-3. 2007
  23. ncbi request reprint Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib
    Bipin N Savani
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10, Hatfield CRC, Room 3 5330, 10 Center Drive MSC 1202, Bethesda, MD 20892 1202, USA
    Lancet Oncol 6:809-12. 2005
  24. pmc Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
    Sumithira Vasu
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:2092-100. 2008
    ..Age, white ethnicity, and female gender were associated with significantly lower post-G-CSF CD34(+) cell counts...
  25. ncbi request reprint Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:22-30. 2006
    ..The contrasting change in central memory cells (CD8(+) increased versus CD4(+) decreased) in cGVHD provide support for recent reports suggesting unique differences in the differentiation pathways for CD8(+) versus CD4(+) T cells...
  26. pmc Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
    Yoshiyuki Takahashi
    Hematology Branch and Flow Cytometry Core Facility, National Heart, Lung, and Blood Institute, Surgery Branch, National Cancer Institute, Department of Clinical Pathology, Clinical Center, Bethesda, Maryland 20892, USA
    J Clin Invest 118:1099-109. 2008
    ..These data suggest that HERV-E is activated in RCC and that it encodes an overexpressed immunogenic antigen, therefore providing a potential target for cellular immunity...
  27. ncbi request reprint Mitochondrial DNA sequence heterogeneity of single CD34+ cells after nonmyeloablative allogeneic stem cell transplantation
    Yong Gang Yao
    Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Building 10 CRC, Room 3E 5140, 10 Center Drive, Bethesda, Maryland 20892 1202, USA
    Stem Cells 25:2670-6. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  28. ncbi request reprint Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation
    Ramaprasad Srinivasan
    Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Br J Haematol 133:305-14. 2006
    ..These data show that HCT following fludarabine-based non-myeloablative conditioning results in durable engraftment and excellent survival in SAA and PNH patients at high risk for graft rejection...
  29. pmc Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation
    Matin M Imanguli
    Clinical Research Core, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 35:184-92. 2007
    ..This study was an initial evaluation of salivary protein changes that occur after allo-HCT...
  30. pmc Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives
    Brenda M Sandmaier
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 13:87-97. 2007
    ..In the future, clinical trials using reduced intensity and nonmyeloablative conditioning will be compared with myeloablative conditioning in selected malignancies to extend the application to standard-risk patients...
  31. ncbi request reprint Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
    Ramaprasad Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
    Exp Hematol 34:796-801. 2006
    ..We investigated serum protein pattern analysis using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry as a tool to diagnose GVHD...
  32. ncbi request reprint Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma
    Darrel Drachenberg
    Cancer Treat Res 116:213-26. 2003
  33. ncbi request reprint In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation
    Yoshiyuki Takahashi
    Hematology Branch and Flow Cytometry Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 1652, USA
    Blood 103:1383-90. 2004
    ..These in vitro and in vivo studies show PNH cells can be immunologically eradicated following nonmyeloablative HCT. Relative to normal cells, no evidence for a decreased sensitivity of PNH cells to T-cell-mediated immunity was observed...
  34. ncbi request reprint Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors
    Cristian Carvallo
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Blood 103:1560-3. 2004
    ..031). Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherapy exposure is an important consideration in trial design...
  35. ncbi request reprint Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement
    Darrel Drachenberg
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Urol Clin North Am 30:611-22. 2003
    ....
  36. ncbi request reprint Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma
    Makoto Satoh
    Department of Urology, Tohoku University School of Medicine, Sendai, Japan
    Lancet Oncol 5:125-6. 2004
  37. ncbi request reprint Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
    ..This finding implies that overrepresentation of CD4(EM) cells is a unique feature of cGVHD...
  38. ncbi request reprint Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
    Takehito Igarashi
    Hematology Branch, Flow Cytometry Core Facility, National Heart, Lund, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Blood 104:170-7. 2004
    ..These data suggest immunotherapeutic strategies that use KIR-incompatible allogeneic NK cells might have superior antineoplastic effects against solid tumors compared with approaches using autologous NK cells...
  39. ncbi request reprint Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells
    Charles D Bolan
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 120:801-7. 2003
    ..This study indicates that a single 25-l apheresis procedure results in similar yields and symptoms, but less donor thrombocytopenia and inconvenience than two consecutive daily 15-l procedures...
  40. ncbi request reprint Immunotherapy of solid tumors: nonmyeloablative allogeneic stem cell transplantation
    Richard W Childs
    Stem Cell Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    MedGenMed 4:13. 2002
  41. ncbi request reprint Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma
    Yoshiyuki Takahashi
    Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892 1652, USA
    Clin Cancer Res 10:6353S-9S. 2004
    ....
  42. ncbi request reprint Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation
    Charles D Bolan
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1184, USA
    Transfusion 42:935-46. 2002
    ..However, neither the metabolic effects nor the management of associated symptoms have been critically evaluated during leukapheresis in healthy donors...
  43. ncbi request reprint Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy
    Igor Espinoza-Delgado
    National Institute on Aging, Section of Hematology Oncology, 5600 Nathan Shock Drive, Room 4C10, Baltimore, MD 21224, USA
    Expert Rev Anticancer Ther 4:865-75. 2004
    ..The development of strategies to decrease graft-versus-host disease while enhancing post-transplant antitumor immunity will hopefully be forthcoming in the near future...
  44. ncbi request reprint Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation
    Peiman Hematti
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 30:943-9. 2002
    ..We investigated the contribution of cells with a primitive hematopoietic phenotype to human epidermal skin formation in recipients of allogeneic mobilized peripheral blood hematopoietic stem cell (HSC) transplantation...
  45. ncbi request reprint Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens
    Scott S Tykodi
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Clin Cancer Res 10:7799-811. 2004
    ..This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma...
  46. ncbi request reprint Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients
    Karoll J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:967-72. 2003
    ..Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clinical use...
  47. ncbi request reprint Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation
    Bipin N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 13:517-20. 2007
    ..Our data shows that BL is a long-term posttransplant complication, and emphasize the importance of serial BMD scans, and the treatment of BL with biphosphonates reserved for worsening BL or additional risk factors...
  48. ncbi request reprint Positron emission tomography for lymphoma staging: tissue remains the issue
    Ramaprasad Srinivasan
    J Natl Cancer Inst 97:611-3. 2005
  49. ncbi request reprint Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride
    Ichio Aoki
    Laboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892 1065, USA
    NMR Biomed 19:50-9. 2006
    ..5 mM MnCl2. This is the first report to describe the use of MnCl2 to label lymphocytes. Our data suggests MnCl2 might be an alternative to iron oxide cell labeling for MRI-based cell migration studies...
  50. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004
  51. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 1
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 11:862-70. 2005
  52. ncbi request reprint Cytotoxins and cancer immunotherapy: the dance of the macabre?
    Carmen J Allegra
    J Natl Cancer Inst 97:1396-7. 2005
  53. ncbi request reprint Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis
    Hillard M Lazarus
    University Hospitals of Cleveland, Cleveland, Ohio 44106, USA
    Biol Blood Marrow Transplant 13:778-89. 2007
    ..Patient selection bias for either transplant approach, however, may affect the results of this observational study; a randomized trial is needed to determine which approach, if either, is better...